DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20221175

Study on serum iron profile in COVID-19 associated mucormycosis patients

Imran Khan, Raghavendra B. M., Vishal S.

Abstract


Background: Mucormycosis is an angio-invasive disease caused by fungi prevalence of which in India is approximately 0.14 cases per 1000 population. The incidence of mucor in COVID 19 patients has increased to greater extent. Probable cause of which is increased serum ferritin among these patients and Iron is required by virtually all microbial pathogens for growth and virulence. Hence, we had conducted a study to estimate serum iron profile and association of iron profile with mucor mycosis in covid-19 associated mucormycosis.

Methods: Cross sectional study conducted from May 2021 to July 2021 by the department of general medicine, Banglore medical college and research centre, Karnataka. The data collected was analyzed statistically using descriptive statistics.

Results: We observed increased prevalence of mucor cases among the patients aged between 41 to 60 years and those who were not vaccinated. Hyperglycaemia had strong correlation with development of mucor. There was lower UIBC, lower TIBC, high ferritin and serum Iron levels among those who had developed mucormycosis.

Conclusions: By our observations, we concluded that the increased serum iron, ferritin, transferrin and reduced TIBC and UIBC are the associated risk factor in the development of COVID 19 associated invasive mucor mycosis. Patients with HbA1c >7 are at higher risk of developing COVID 19 associated mucor mycosis.


Keywords


COVID 19, Mucormycosis, Serum iron profile, UIBC, TIBC, Ferritin

Full Text:

PDF

References


20200121-sitrep-1-2019-ncov.pdf. Available at: https://www.who.int/docs/default-source/coronavi ruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf. Accessed on 4 May 2021.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054-62.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207.

Pal R, Yadav U. COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead. J Prim Care Community Health. 2020;11:215013272093940.

MoHFW. Available at: https://www.mohf w.gov.in/index.html. Accessed on 4 May 2021.

Mucormycosis: The 'black fungus' maiming Covid patients in India. BBC News. 2021. Available at: https://www.bbc.com/news/world-asia-india-570 27829. Accessed on1 June 2021.

The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi. 2021;7(4):298.

Singh AK. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. 2021;28.

Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthal Plast Reconstr Surg. 2021;37(2):e40-80.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. Clin Infect Dis. 2012;54(1):S16-22.

Kumar HM, Sharma P, Rudramurthy SM, Sehgal IS, Prasad KT, Pannu AK et al. Serum iron indices in COVID-19-associated mucormycosis: A case-control study. Mycoses. 2022;65(1):120-7.

Bhanuprasad K, Manesh A, Devasagayam E, Varghese L, Cherian LM, Kurien R et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis. 2021;111:267-270.

Patel A, Agarwal R, Rudramurthy SM. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis. 2021;27(9):1-12.

Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-85.

Karp JE, Merz WG. Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients. J Clin Oncol. 1986;4(2):216-20.

Abe F, Shibuya H, Tateyama M, Ommura Y, Azumi N, Kimura K. Mucormycosis in diabetic ketoacidosis. Role of unbound iron binding capacity of transferrin. Acta Pathol Jpn. 1986;36(10):1507-12.